JP2020508992A - ざ瘡の処置のためのカンナビノイドの製剤 - Google Patents

ざ瘡の処置のためのカンナビノイドの製剤 Download PDF

Info

Publication number
JP2020508992A
JP2020508992A JP2019544845A JP2019544845A JP2020508992A JP 2020508992 A JP2020508992 A JP 2020508992A JP 2019544845 A JP2019544845 A JP 2019544845A JP 2019544845 A JP2019544845 A JP 2019544845A JP 2020508992 A JP2020508992 A JP 2020508992A
Authority
JP
Japan
Prior art keywords
cbd
pharmaceutical composition
alcohol
skin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019544845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508992A5 (enExample
Inventor
ユージーン クーパー，
ユージーン クーパー，
マシュー カラハン，
マシュー カラハン，
Original Assignee
ボタニクス ファーマシューティカルズ リミテッド
ボタニクス ファーマシューティカルズ リミテッド
ボタニクス ファーマシューティカルズ， インコーポレイテッド
ボタニクス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900493A external-priority patent/AU2017900493A0/en
Application filed by ボタニクス ファーマシューティカルズ リミテッド, ボタニクス ファーマシューティカルズ リミテッド, ボタニクス ファーマシューティカルズ， インコーポレイテッド, ボタニクス ファーマシューティカルズ， インコーポレイテッド filed Critical ボタニクス ファーマシューティカルズ リミテッド
Priority claimed from PCT/AU2018/050045 external-priority patent/WO2018148786A1/en
Publication of JP2020508992A publication Critical patent/JP2020508992A/ja
Publication of JP2020508992A5 publication Critical patent/JP2020508992A5/ja
Priority to JP2022166140A priority Critical patent/JP2022185150A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
JP2019544845A 2017-02-15 2018-01-24 ざ瘡の処置のためのカンナビノイドの製剤 Withdrawn JP2020508992A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022166140A JP2022185150A (ja) 2017-02-15 2022-10-17 ざ瘡の処置のためのカンナビノイドの製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762459313P 2017-02-15 2017-02-15
US62/459,313 2017-02-15
AU2017900493 2017-02-15
AU2017900493A AU2017900493A0 (en) 2017-02-15 Formulations of Cannabinoids for the Treatment of Acne
PCT/AU2018/050045 WO2018148786A1 (en) 2017-02-15 2018-01-24 Formulations of cannabinoids for the treatment of acne

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022166140A Division JP2022185150A (ja) 2017-02-15 2022-10-17 ざ瘡の処置のためのカンナビノイドの製剤

Publications (2)

Publication Number Publication Date
JP2020508992A true JP2020508992A (ja) 2020-03-26
JP2020508992A5 JP2020508992A5 (enExample) 2020-12-17

Family

ID=67766784

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019544845A Withdrawn JP2020508992A (ja) 2017-02-15 2018-01-24 ざ瘡の処置のためのカンナビノイドの製剤
JP2022166140A Pending JP2022185150A (ja) 2017-02-15 2022-10-17 ざ瘡の処置のためのカンナビノイドの製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022166140A Pending JP2022185150A (ja) 2017-02-15 2022-10-17 ざ瘡の処置のためのカンナビノイドの製剤

Country Status (9)

Country Link
US (1) US20220323401A1 (enExample)
EP (1) EP3582770A4 (enExample)
JP (2) JP2020508992A (enExample)
CN (1) CN110769819A (enExample)
AU (1) AU2018221881B2 (enExample)
BR (1) BR112019017049A2 (enExample)
CA (1) CA3053503C (enExample)
IL (1) IL268728B2 (enExample)
NZ (1) NZ756307A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022185150A (ja) * 2017-02-15 2022-12-13 ボタニクス ファーマシューティカルズ リミテッド ざ瘡の処置のためのカンナビノイドの製剤

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021173800A1 (en) * 2020-02-25 2021-09-02 Advanced Animal Diagnostics, Inc. Methods and compositions for identifiying a survivability index for an animal
CN114073687A (zh) * 2020-08-21 2022-02-22 四川大学华西医院 大麻二酚在制备防治玫瑰痤疮的药物中的用途
CN113372196B (zh) * 2021-07-02 2022-09-30 江南大学 8,9-二氢大麻二酚及其合成方法与应用
JP7736309B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736308B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736306B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736310B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536854A (ja) * 2001-07-18 2004-12-09 ユニリーバー・ナームローゼ・ベンノートシヤープ 頭髪及び／または頭皮のトリートメント組成物
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
US20150297556A1 (en) * 2014-04-18 2015-10-22 Mary's Medicinals LLC Transdermal cannabinoid patch
US20160374958A1 (en) * 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids
JP2020508994A (ja) * 2017-02-15 2020-03-26 ボタニクス ファーマシューティカルズ リミテッド 皮膚炎および炎症性皮膚疾患の処置のためのカンナビノイドの製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0104268D0 (en) * 2001-02-21 2001-04-11 Unilever Plc Antiperspirant or deodorant compositions
WO2009090495A2 (en) * 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
WO2010127033A1 (en) * 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
EP2444081B1 (en) * 2010-10-19 2015-04-08 Parenteral, A.S. A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
NZ707855A (en) * 2012-11-06 2018-11-30 Rochal Ind Llc Delivery of biologically-active agents using volatile, hydrophobic solvents
WO2014116653A1 (en) * 2013-01-22 2014-07-31 Coty Inc. Topical formulations and methods for the use thereof
EP3265081A4 (en) * 2015-03-02 2018-11-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
JP2020508992A (ja) * 2017-02-15 2020-03-26 ボタニクス ファーマシューティカルズ リミテッド ざ瘡の処置のためのカンナビノイドの製剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536854A (ja) * 2001-07-18 2004-12-09 ユニリーバー・ナームローゼ・ベンノートシヤープ 頭髪及び／または頭皮のトリートメント組成物
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
US20150297556A1 (en) * 2014-04-18 2015-10-22 Mary's Medicinals LLC Transdermal cannabinoid patch
US20160374958A1 (en) * 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids
JP2020508994A (ja) * 2017-02-15 2020-03-26 ボタニクス ファーマシューティカルズ リミテッド 皮膚炎および炎症性皮膚疾患の処置のためのカンナビノイドの製剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EXPERIMETAL DERMATOLOGY, vol. 25, JPN6021042213, 2016, pages 701 - 707, ISSN: 0004624417 *
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 124, no. 9, JPN6021042215, 2014, pages 3713 - 3724, ISSN: 0004624416 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022185150A (ja) * 2017-02-15 2022-12-13 ボタニクス ファーマシューティカルズ リミテッド ざ瘡の処置のためのカンナビノイドの製剤

Also Published As

Publication number Publication date
US20220323401A1 (en) 2022-10-13
AU2018221881A1 (en) 2019-09-05
JP2022185150A (ja) 2022-12-13
EP3582770A4 (en) 2020-11-18
BR112019017049A2 (pt) 2020-04-14
CA3053503C (en) 2024-04-23
NZ756307A (en) 2023-01-27
IL268728B2 (en) 2024-09-01
CA3053503A1 (en) 2018-08-23
AU2018221881B2 (en) 2023-09-14
IL268728B1 (en) 2024-05-01
IL268728A (en) 2019-10-31
EP3582770A1 (en) 2019-12-25
CN110769819A (zh) 2020-02-07

Similar Documents

Publication Publication Date Title
JP2022185150A (ja) ざ瘡の処置のためのカンナビノイドの製剤
JP7012089B2 (ja) 皮膚炎および炎症性皮膚疾患の処置のためのカンナビノイドの製剤
WO2018148786A1 (en) Formulations of cannabinoids for the treatment of acne
WO2018148785A1 (en) Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
WO2018148787A1 (en) Formulations of cannabinoids for the treatment of psoriasis
Salau et al. Enhancement of transdermal permeation of cannabinoids and their pharmacodynamic evaluation in rats
US20240325393A1 (en) Tofacitinib-containing anhydrous elastomer-based gel formulations
JP2024012288A (ja) ざ瘡のためのカンナビノイド投薬レジメン
Pan et al. Oleogel-mediated Topical Administration of Roflumilast and Paclitaxel as a Synergistic Strategy to Combat Imiquimod-induced Psoriasis
US20220313621A1 (en) Formulations of cannabinoids for the treatment of psoriasis
US20230320984A1 (en) Tofacitinib-containing anhydrous elastomer-based gel formulations
JP2020508993A (ja) ざ瘡を処置するための組成物
WO2018148795A1 (en) Compositions for treating acne

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221017

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221017

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221116

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221117

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20221122